More patients with oligoarticular psoriatic arthritis (PsA) saw symptoms largely disappear when apremilast (Otezla) was started early in the disease course compared with placebo, a randomized trial ...

Please provide your email address to receive an email when new articles are posted on . Apremilast led to better clinical outcomes in early oligoarticular PsA vs. placebo at 16 weeks. Safety was ...

WASHINGTON — In the phase 3 PALACE-1 trial, the investigational agent apremilast led to significant improvement in the signs and symptoms of psoriatic arthritis (PsA) in patients who failed to respond ...

Please provide your email address to receive an email when new articles are posted on . PASI and static Physician Global Assessment scores significantly improved in pediatric patients with psoriasis ...

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

Celgene announced results from PALACE-1, the Company’s first Phase 3 study of apremilast in psoriatic arthritis. Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works ...

A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity-two issues ...

Credit: Thinkstock. Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor. Risankizumab (Skyrizi ®) was found to significantly improve clinical outcomes in patients ...

The US FDA has recently given approval for the use of apremilast (Otezla ®, Celgene, USA), an oral phosphodiesterase-4 (PDE-4) inhibitor, in adults with active psoriatic arthritis (PsA). 1 For a ...

Learn everything you need to know about Apremilast-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Apremilast (Otezla), an oral drug approved for adult psoriasis, appears to reduce psoriasis severity in some children with moderate to severe psoriasis not controlled by topical therapy, according to ...

The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet’s syndrome. In a phase 2 trial involving patients with Behçet’s syndrome, apremilast ...